| John Joseph Naponick, MD CM MPH TM | |
|
5604b Coliseum Blvd, Alexandria, LA 71303-3709 | |
| (318) 487-5261 | |
| (318) 483-5363 |
| Full Name | John Joseph Naponick |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Public Health & General Preventive Medicine |
| Location | 5604b Coliseum Blvd, Alexandria, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730181546 | NPI | - | NPPES |
| 1437743 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083P0901X | Preventive Medicine - Public Health & General Preventive Medicine | MD 012519 (Louisiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| John Joseph Naponick, MD CM MPH TM 5604b Coliseum Blvd, Alexandria, LA 71303-3709 Ph: (318) 487-5261 | John Joseph Naponick, MD CM MPH TM 5604b Coliseum Blvd, Alexandria, LA 71303-3709 Ph: (318) 487-5261 |
News Archive
AIDS Healthcare Foundation (AHF) has urged Tibotec Pharmaceuticals Ltd., a division of Johnson & Johnson, to reconsider and reduce its steep price for its newest AIDS drug, etravirine (TMC 125), a non-nucleoside reverse transcriptase inhibitor, (NNRTI), which received Food and Drug Administration (FDA) approval on Friday after a fast track or 'priority review' and approval process granted to companies for medications and therapies intended to treat life-threatening illnesses such as AIDS.
A substance in human mesenchymal stem cells that promotes growth appears to spur restoration of nerves and their function in rodent models of multiple sclerosis (MS), researchers at Case Western Reserve University School of Medicine have found.
Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.
Dapagliflozin, a drug commonly used to treat type 2 diabetes, improved symptoms and physical limitations in patients with heart failure with preserved ejection fraction, according to clinical trial results published in Nature Medicine.
› Verified 9 days ago
Max Travis Mahaffey, ATC, LAT Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 3347 Masonic Dr, Alexandria, LA 71301 Phone: 318-448-4959 |